MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations

Opinion
Video

The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.

Video content above is prompted by the following questions:

  • How might you consider sequencing therapies for this patient? Please describe how you would approach treating this patient in your practice.
    • What factors impact your decision?
    • How do you incorporate patient preferences and quality of life considerations into the discussion when determining the sequencing of bispecifics and CAR T-cell therapy in R/R MM?
  • Can BCMA-targeting bispecifics be used in patients who have received prior BCMA targeting CAR-T therapies?
    • Might you consider a different target?
  • Might your strategy differ if the patient had received ide-cel instead of cilta-cel?
Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content